Medical therapy for Crohn's disease: the state of the art. (Q34161820)

31 July 2017

1 reference

title

Medical therapy for Crohn's disease: the state of the art. (English)

1 reference

31 July 2017

0 references

Stein RB

1

1 reference

PubMed ID

11218170

31 July 2017

Lichtenstein GR

series ordinal

2

1 reference

31 July 2017

1 February 2001

1 reference

Surgical Clinics of North America

31 July 2017

1 reference

31 July 2017

81

1 reference

31 July 2017

1

1 reference

31 July 2017

71-101, viii

1 reference

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

The relationship between infliximab treatment and lymphoma in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

The risk of neoplasms in patients treated with cyclosporine A.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mycophenolate mofetil in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Inflammatory bowel disease: etiology and pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Combination ciprofloxacin and metronidazole for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Optimum duration of treatment with 6-mercaptopurine for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Hyperbaric oxygen for perianal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Treatment of fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Parenteral nutrition in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

The mechanism of action of cyclosporin A and FK506

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Medical therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Newer treatments for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Sulfasalazine. Adverse effects and desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

Use of an intravenous steroid regimen in the treatment of acute Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970274-7

7 January 2021

10.1016/S0039-6109(05)70274-7

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11218170